Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate without
neuroendocrine differentiation or small cell histology

- Received at least 1 but not more than 2 cytotoxic chemotherapy regimens for
metastatic castration resistant prostate cancer (CRPC) (at least 1 regimen must have
contained a taxane such as docetaxel; if a chemotherapy regimen containing a taxane
is used more than once, this will be considered as 1 regimen)

- Agrees to protocol-defined use of effective contraception

- Laboratory values within protocol -defined parameters

Exclusion Criteria:

- Serious or uncontrolled co-existent non-malignant disease, including active and
uncontrolled infection

- Abnormal liver function

- Uncontrolled hypertension (systolic blood pressure >=160 mmHg or diastolic blood
pressure >=95 mmHg)

- Active or symptomatic viral hepatitis or chronic liver disease

- History of pituitary or adrenal dysfunction

- Clinically significant heart disease as evidenced by myocardial infarction, or
arterial thrombotic events in the past 6 months, severe or unstable angina, or New
York Heart Association (NYHA) Class III or IV heart disease or left ventricular
ejection fraction of <50% at baseline

- Known brain metastasis

- History of gastrointestinal disorders (medical disorders or extensive surgery) that
may interfere with the absorption of the study drug

- Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved
to a NCI-CTCAE (Version 4.0) Grade of <=1

- Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole,
ketoconazole) within 4 weeks of Cycle 1, Day 1

- Condition or situation which, in the investigator's opinion, may put the patient at
significant risk, may confound the study results, or may interfere significantly with
patient's participation in the study

- Participation in an investigational drug trial within 30 days prior to selection

- Known hypersensitivity to abiraterone acetate, or to any of the components in the
formulation